Tavapadon phase 3 trial shows significant improvement in motor function and daily activities for people with early Parkinson's

A new clinical trial has provided promising results for a potential new treatment option for people in the early stages of Parkinson's. The study, known as TEMPO-1, looked at a drug called tavapadon, which works by specifically targeting the D1 and D5 dopamine receptors in the brain. Unlike some current treatments that can affect a wide range of receptors, this more targeted approach aims to provide the necessary dopamine boost while potentially reducing some common side effects. The trial involved over 500 adults who had been living with Parkinson's for less than three years. Participants were divided into groups receiving either a 5 mg dose, a 15 mg dose, or a placebo once a day. The researchers were particularly interested in how the drug affected both physical movement and the ability to carry out everyday tasks, such as dressing or eating. By the fifth week of the study, those taking tavapadon began to show noticeable improvements compared to the group receiving the placebo. These benefits continued to grow and were sustained throughout the entire 26-week period. On a standard scale used to measure the impact of Parkinson's, those on the medication saw their scores drop significantly—by around 10 points—while the placebo group actually saw a slight increase in their symptom scores. Beyond the clinical measurements, the people taking part in the study reported a clear difference in their own lives. Nearly half of the participants in the tavapadon groups felt they were "much improved" or "very much improved," a much higher rate than the 12% reported in the placebo group. This suggests that the changes measured by the researchers translated into a meaningful bettering of daily life for the participants. In terms of safety, the drug was generally well tolerated. The most common issues reported were mild to moderate, such as nausea, headaches, or dizziness. Importantly, the study found that rates of daytime sleepiness and impulse control issues—which can sometimes be a concern with dopamine-related medications—were low and similar to those who were not taking the active drug. While the results are encouraging, the researchers noted that the study primarily included White participants and lasted for about six months. More research will be needed to see how the drug performs across more diverse populations and over a longer period of time. However, this trial marks a significant step forward in finding new ways to support people in the early years of living with the condition.